{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:34:28Z","timestamp":1793709268051,"version":"4.6.1"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"8054","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2025,3,13]]},"DOI":"10.1038\/s41586-024-08507-5","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T16:05:18Z","timestamp":1738771518000},"page":"474-482","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":233,"title":["A neoantigen vaccine generates antitumour immunity in renal cell carcinoma"],"prefix":"10.1038","volume":"639","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4543-5553","authenticated-orcid":false,"given":"David A.","family":"Braun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8065-6277","authenticated-orcid":false,"given":"Giorgia","family":"Moranzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6592-8710","authenticated-orcid":false,"given":"Vipheaviny","family":"Chea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8298-0289","authenticated-orcid":false,"given":"Bradley A.","family":"McGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eryn","family":"Blass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe R.","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison P.","family":"Vanasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cleo","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander B.","family":"Afeyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas R.","family":"Schindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9106-6141","authenticated-orcid":false,"given":"Shuqiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackson","family":"Southard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven L.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle S.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole R.","family":"LeBoeuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Olive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambica","family":"Mehndiratta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley","family":"Greenslade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keerthi","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0074-5163","authenticated-orcid":false,"given":"Susan","family":"Klaeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siranush","family":"Sarkizova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina B.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Mossanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Carulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tarren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Duke-Cohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis A.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Bryan","family":"Iorgulescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohoon","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3906-1663","authenticated-orcid":false,"given":"Jeremy M.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5000-9105","authenticated-orcid":false,"given":"Sabina","family":"Signoretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon C.","family":"Aster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liudmila","family":"Elagina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7203-4299","authenticated-orcid":false,"given":"Steven A.","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignaty","family":"Leshchiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0936-0753","authenticated-orcid":false,"given":"Gad","family":"Getz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2349-2656","authenticated-orcid":false,"given":"Nir","family":"Hacohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars R.","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7435-5603","authenticated-orcid":false,"given":"Giacomo","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2566-3145","authenticated-orcid":false,"given":"Donna S.","family":"Neuberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9105-5856","authenticated-orcid":false,"given":"Kenneth J.","family":"Livak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2445-3584","authenticated-orcid":false,"given":"Sachet A.","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8412-5665","authenticated-orcid":false,"given":"Edward F.","family":"Fritsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3348-5054","authenticated-orcid":false,"given":"Catherine J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derin B.","family":"Keskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4253-943X","authenticated-orcid":false,"given":"Patrick A.","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9201-3217","authenticated-orcid":false,"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"8507_CR1","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403, 632\u2013644 (2024).","journal-title":"Lancet"},{"key":"8507_CR2","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144\u2013150 (2023).","journal-title":"Nature"},{"key":"8507_CR3","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","volume":"565","author":"DB Keskin","year":"2019","unstructured":"Keskin, D. B. et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565, 234\u2013239 (2019).","journal-title":"Nature"},{"key":"8507_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217\u2013221 (2017).","journal-title":"Nature"},{"key":"8507_CR5","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","volume":"27","author":"Z Hu","year":"2021","unstructured":"Hu, Z. et al. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat. Med. 27, 515\u2013525 (2021).","journal-title":"Nat. Med."},{"key":"8507_CR6","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222\u2013226 (2017).","journal-title":"Nature"},{"key":"8507_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69\u201374 (2015).","journal-title":"Science"},{"key":"8507_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1158\/2326-6066.CIR-13-0022","volume":"1","author":"N Hacohen","year":"2013","unstructured":"Hacohen, N., Fritsch, E. F., Carter, T. A., Lander, E. S. & Wu, C. J. Getting personal with neoantigen-based therapeutic cancer vaccines. Cancer Immunol. Res. 1, 11\u201315 (2013).","journal-title":"Cancer Immunol. Res."},{"key":"8507_CR9","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214\u2013218 (2013).","journal-title":"Nature"},{"key":"8507_CR10","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/s41591-020-0839-y","volume":"26","author":"DA Braun","year":"2020","unstructured":"Braun, D. A. et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat. Med. 26, 909\u2013918 (2020).","journal-title":"Nat. Med."},{"key":"8507_CR11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ucl.2023.01.012","volume":"50","author":"S Kashima","year":"2023","unstructured":"Kashima, S. & Braun, D. A. The changing landscape of immunotherapy for advanced renal cancer. Urol. Clin. North Am. 50, 335\u2013349 (2023).","journal-title":"Urol. Clin. North Am."},{"key":"8507_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","volume":"160","author":"MS Rooney","year":"2015","unstructured":"Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48\u201361 (2015).","journal-title":"Cell"},{"key":"8507_CR13","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","volume":"20","author":"D Bruni","year":"2020","unstructured":"Bruni, D., Angell, H. K. & Galon, J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat. Rev. Cancer 20, 662\u2013680 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"8507_CR14","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMoa2106391","volume":"385","author":"TK Choueiri","year":"2021","unstructured":"Choueiri, T. K. et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N. Engl. J. Med. 385, 683\u2013694 (2021).","journal-title":"N. Engl. J. Med."},{"key":"8507_CR15","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S0140-6736(22)02574-0","volume":"401","author":"RJ Motzer","year":"2023","unstructured":"Motzer, R. J. et al. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. Lancet 401, 821\u2013832 (2023).","journal-title":"Lancet"},{"key":"8507_CR16","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/S0140-6736(22)01658-0","volume":"400","author":"SK Pal","year":"2022","unstructured":"Pal, S. K. et al. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Lancet 400, 1103\u20131116 (2022).","journal-title":"Lancet"},{"key":"8507_CR17","doi-asserted-by":"publisher","first-page":"S1432","DOI":"10.1016\/j.annonc.2022.08.072","volume":"33","author":"M Allaf","year":"2022","unstructured":"Allaf, M. et al. LBA67 phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial. Ann. Oncol. 33, S1432\u2013S1433 (2022).","journal-title":"Ann. Oncol."},{"key":"8507_CR18","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/S0140-6736(04)15590-6","volume":"363","author":"D Jocham","year":"2004","unstructured":"Jocham, D. et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363, 594\u2013599 (2004).","journal-title":"Lancet"},{"key":"8507_CR19","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/S1470-2045(16)30408-9","volume":"17","author":"BI Rini","year":"2016","unstructured":"Rini, B. I. et al. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 17, 1599\u20131611 (2016).","journal-title":"Lancet Oncol."},{"key":"8507_CR20","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/iju.15077","volume":"30","author":"F Hongo","year":"2023","unstructured":"Hongo, F. et al. Phase I\/II study of multipeptide cancer vaccine IMA901 after single-dose cyclophosphamide in Japanese patients with advanced renal cell cancer with long-term follow up. Int. J. Urol. 30, 176\u2013180 (2023).","journal-title":"Int. J. Urol."},{"key":"8507_CR21","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1200\/jco.2004.22.90140.2589","volume":"22","author":"MS Achtar","year":"2004","unstructured":"Achtar, M. S. et al. Vaccine therapy with tumor specific mutated VHL peptides in adult cancer patients with renal cell carcinoma. J. Clin. Oncol. 22, 2589 (2004).","journal-title":"J. Clin. Oncol."},{"key":"8507_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-8-8","volume":"8","author":"OE Rahma","year":"2010","unstructured":"Rahma, O. E. et al. A pilot clinical trial testing mutant von Hippel\u2013Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma. J. Transl. Med. 8, 8 (2010).","journal-title":"J. Transl. Med."},{"key":"8507_CR23","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S1470-2045(22)00487-9","volume":"23","author":"T Powles","year":"2022","unstructured":"Powles, T. et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 23, 1133\u20131144 (2022).","journal-title":"Lancet Oncol."},{"key":"8507_CR24","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/jid.2011.346","volume":"132","author":"C Liard","year":"2012","unstructured":"Liard, C. et al. Intradermal immunization triggers epidermal Langerhans cell mobilization required for CD8 T-cell immune responses. J. Invest. Dermatol. 132, 615\u2013625 (2012).","journal-title":"J. Invest. Dermatol."},{"key":"8507_CR25","doi-asserted-by":"publisher","first-page":"418","DOI":"10.4049\/jimmunol.181.1.418","volume":"181","author":"E Shklovskaya","year":"2008","unstructured":"Shklovskaya, E., Roediger, B. & Fazekas de St Groth, B. Epidermal and dermal dendritic cells display differential activation and migratory behavior while sharing the ability to stimulate CD4+ T cell proliferation in vivo. J. Immunol. 181, 418\u2013430 (2008).","journal-title":"J. Immunol."},{"key":"8507_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-immunol-100311-102839","volume":"30","author":"RM Steinman","year":"2012","unstructured":"Steinman, R. M. Decisions about dendritic cells: past, present, and future. Annu. Rev. Immunol. 30, 1\u201322 (2012).","journal-title":"Annu. Rev. Immunol."},{"key":"8507_CR27","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1084\/jem.20090247","volume":"206","author":"MP Longhi","year":"2009","unstructured":"Longhi, M. P. et al. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J. Exp. Med. 206, 1589\u20131602 (2009).","journal-title":"J. Exp. Med."},{"key":"8507_CR28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-021-03704-y","volume":"596","author":"G Oliveira","year":"2021","unstructured":"Oliveira, G. et al. Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. Nature 596, 119\u2013125 (2021).","journal-title":"Nature"},{"key":"8507_CR29","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1016\/j.cell.2022.06.035","volume":"185","author":"MC Sellars","year":"2022","unstructured":"Sellars, M. C., Wu, C. J. & Fritsch, E. F. Cancer vaccines: building a bridge over troubled waters. Cell 185, 2770\u20132788 (2022).","journal-title":"Cell"},{"key":"8507_CR30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nature12222","volume":"499","author":"Cancer Genome Atlas Research Network.","year":"2013","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43\u201349 (2013).","journal-title":"Nature"},{"key":"8507_CR31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00345-013-1033-3","volume":"32","author":"J Bedke","year":"2014","unstructured":"Bedke, J. et al. Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy. World J. Urol. 32, 31\u201338 (2014).","journal-title":"World J. Urol."},{"key":"8507_CR32","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1053\/j.seminoncol.2006.06.011","volume":"33","author":"H Kubler","year":"2006","unstructured":"Kubler, H. & Vieweg, J. Vaccines in renal cell carcinoma. Semin. Oncol. 33, 614\u2013624 (2006).","journal-title":"Semin. Oncol."},{"key":"8507_CR33","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/S0140-6736(04)16169-2","volume":"363","author":"S Kommu","year":"2004","unstructured":"Kommu, S. Renal-cell carcinoma: vaccination and risk of tumour progression. Lancet 363, 1557 (2004).","journal-title":"Lancet"},{"key":"8507_CR34","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","volume":"183","author":"PA Ott","year":"2020","unstructured":"Ott, P. A. et al. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell 183, 347\u2013362 (2020).","journal-title":"Cell"},{"key":"8507_CR35","doi-asserted-by":"publisher","first-page":"CT169","DOI":"10.1158\/1538-7445.AM2020-CT169","volume":"80","author":"F Braiteh","year":"2020","unstructured":"Braiteh, F. et al. Abstract CT169: a phase Ia study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in patients with locally advanced or metastatic solid tumors. Cancer Res. 80, CT169 (2020).","journal-title":"Cancer Res."},{"key":"8507_CR36","doi-asserted-by":"publisher","first-page":"CT001","DOI":"10.1158\/1538-7445.AM2023-CT001","volume":"83","author":"A Khattak","year":"2023","unstructured":"Khattak, A. et al. Abstract CT001: a personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: efficacy and safety results from the randomized, open-label phase 2 mRNA-4157-P201\/Keynote-942 trial. Cancer Res. 83, CT001 (2023).","journal-title":"Cancer Res."},{"key":"8507_CR37","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1158\/1078-0432.CCR-21-2834","volume":"28","author":"M Liu","year":"2022","unstructured":"Liu, M. et al. Improved T-cell immunity following neoadjuvant chemotherapy in ovarian cancer. Clin. Cancer Res. 28, 3356\u20133366 (2022).","journal-title":"Clin. Cancer Res."},{"key":"8507_CR38","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.ccell.2021.02.013","volume":"39","author":"DA Braun","year":"2021","unstructured":"Braun, D. A. et al. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell 39, 632\u2013648 (2021).","journal-title":"Cancer Cell"},{"key":"8507_CR39","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1038\/s41591-022-01937-6","volume":"28","author":"CD Palmer","year":"2022","unstructured":"Palmer, C. D. et al. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nat. Med. 28, 1619\u20131629 (2022).","journal-title":"Nat. Med."},{"key":"8507_CR40","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer, R. et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N. Engl. J. Med. 384, 1289\u20131300 (2021).","journal-title":"N. Engl. J. Med."},{"key":"8507_CR41","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri, T. K. et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 384, 829\u2013841 (2021).","journal-title":"N. Engl. J. Med."},{"key":"8507_CR42","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer, R. J. et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1103\u20131115 (2019).","journal-title":"N. Engl. J. Med."},{"key":"8507_CR43","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini, B. I. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1116\u20131127 (2019).","journal-title":"N. Engl. J. Med."},{"key":"8507_CR44","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277\u20131290 (2018).","journal-title":"N. Engl. J. Med."},{"key":"8507_CR45","doi-asserted-by":"publisher","first-page":"107827","DOI":"10.1016\/j.celrep.2020.107827","volume":"31","author":"KE Pauken","year":"2020","unstructured":"Pauken, K. E. et al. The PD-1 pathway regulates development and function of memory CD8+ T cells following respiratory viral infection. Cell Rep. 31, 107827 (2020).","journal-title":"Cell Rep."},{"key":"8507_CR46","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/s41590-019-0441-y","volume":"20","author":"V Verma","year":"2019","unstructured":"Verma, V. et al. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. Nat. Immunol. 20, 1231\u20131243 (2019).","journal-title":"Nat. Immunol."},{"key":"8507_CR47","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","volume":"8","author":"Y Agata","year":"1996","unstructured":"Agata, Y. et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8, 765\u2013772 (1996).","journal-title":"Int. Immunol."},{"key":"8507_CR48","doi-asserted-by":"publisher","first-page":"100470","DOI":"10.1016\/j.cobme.2023.100470","volume":"28","author":"Z Azari","year":"2023","unstructured":"Azari, Z. et al. The role of immune cells in therapeutic angiogenesis: concepts in tissue engineering. Curr. Opin. Biomed. Eng. 28, 100470 (2023).","journal-title":"Curr. Opin. Biomed. Eng."},{"key":"8507_CR49","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1161\/01.RES.0000153188.68898.ac","volume":"96","author":"S Frantz","year":"2005","unstructured":"Frantz, S., Vincent, K. A., Feron, O. & Kelly, R. A. Innate immunity and angiogenesis. Circ. Res. 96, 15\u201326 (2005).","journal-title":"Circ. Res."},{"key":"8507_CR50","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abd2712","volume":"6","author":"N Patsoukis","year":"2020","unstructured":"Patsoukis, N., Wang, Q., Strauss, L. & Boussiotis, V. A. Revisiting the PD-1 pathway. Sci. Adv. 6, eabd2712 (2020).","journal-title":"Sci. Adv."},{"key":"8507_CR51","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.imlet.2011.11.001","volume":"142","author":"X Frigola","year":"2012","unstructured":"Frigola, X. et al. Soluble B7-H1: differences in production between dendritic cells and T cells. Immunol. Lett. 142, 78\u201382 (2012).","journal-title":"Immunol. Lett."},{"key":"8507_CR52","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2018","unstructured":"Sharpe, A. H. & Pauken, K. E. The diverse functions of the PD1 inhibitory pathway. Nat. Rev. Immunol. 18, 153\u2013167 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"8507_CR53","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","volume":"18","author":"J Borst","year":"2018","unstructured":"Borst, J., Ahrends, T., Babala, N., Melief, C. J. M. & Kastenmuller, W. CD4+ T cell help in cancer immunology and immunotherapy. Nat. Rev. Immunol. 18, 635\u2013647 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"8507_CR54","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.ccell.2024.05.025","volume":"42","author":"G Espinosa-Carrasco","year":"2024","unstructured":"Espinosa-Carrasco, G. et al. Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors. Cancer Cell 42, 1202\u20131216 (2024).","journal-title":"Cancer Cell"},{"key":"8507_CR55","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","volume":"21","author":"M Saxena","year":"2021","unstructured":"Saxena, M., van der Burg, S. H., Melief, C. J. M. & Bhardwaj, N. Therapeutic cancer vaccines. Nat. Rev. Cancer 21, 360\u2013378 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"8507_CR56","doi-asserted-by":"publisher","unstructured":"Albiges, L., Flippot, R., Rioux-Leclercq, N. & Choueiri, T. K. Non-clear cell renal cell carcinomas: from shadow to light. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2018.79.2531 (2018).","DOI":"10.1200\/JCO.2018.79.2531"},{"key":"8507_CR57","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","volume":"390","author":"TK Choueiri","year":"2024","unstructured":"Choueiri, T. K. et al. Overall survival with adjuvant pembrolizumab in renal-cell carcinoma. N. Engl. J. Med. 390, 1359\u20131371 (2024).","journal-title":"N. Engl. J. Med."},{"key":"8507_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01308-8","volume":"21","author":"N Liu","year":"2021","unstructured":"Liu, N., Zhou, Y. & Lee, J. J. IPDfromKM: reconstruct individual patient data from published Kaplan\u2013Meier survival curves. BMC Med. Res. Methodol. 21, 111 (2021).","journal-title":"BMC Med. Res. Methodol."},{"key":"8507_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2011-12-1-r1","volume":"12","author":"S Fisher","year":"2011","unstructured":"Fisher, S. et al. A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. Genome Biol. 12, R1 (2011).","journal-title":"Genome Biol."},{"key":"8507_CR60","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ccell.2020.12.007","volume":"39","author":"C Huang","year":"2021","unstructured":"Huang, C. et al. Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. Cancer Cell 39, 361\u2013379 (2021).","journal-title":"Cancer Cell"},{"key":"8507_CR61","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41592-018-0036-9","volume":"15","author":"A Taylor-Weiner","year":"2018","unstructured":"Taylor-Weiner, A. et al. DeTiN: overcoming tumor-in-normal contamination. Nat. Methods 15, 531\u2013534 (2018).","journal-title":"Nat. Methods"},{"key":"8507_CR62","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1093\/bioinformatics\/btr446","volume":"27","author":"K Cibulskis","year":"2011","unstructured":"Cibulskis, K. et al. ContEst: estimating cross-contamination of human samples in next-generation sequencing data. Bioinformatics 27, 2601\u20132602 (2011).","journal-title":"Bioinformatics"},{"key":"8507_CR63","first-page":"656","volume":"12","author":"WJ Kent","year":"2002","unstructured":"Kent, W. J. BLAT\u2014the BLAST-like alignment tool. Genome Res. 12, 656\u2013664 (2002).","journal-title":"Genome Res."},{"key":"8507_CR64","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213\u2013219 (2013).","journal-title":"Nat. Biotechnol."},{"key":"8507_CR65","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1093\/bioinformatics\/bts271","volume":"28","author":"CT Saunders","year":"2012","unstructured":"Saunders, C. T. et al. Strelka: accurate somatic small-variant calling from sequenced tumor\u2013normal sample pairs. Bioinformatics 28, 1811\u20131817 (2012).","journal-title":"Bioinformatics"},{"key":"8507_CR66","doi-asserted-by":"publisher","first-page":"E2423","DOI":"10.1002\/humu.22771","volume":"36","author":"AH Ramos","year":"2015","unstructured":"Ramos, A. H. et al. Oncotator: cancer variant annotation tool. Hum. Mutat. 36, E2423\u2013E2429 (2015).","journal-title":"Hum. Mutat."},{"key":"8507_CR67","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nbt.2203","volume":"30","author":"SL Carter","year":"2012","unstructured":"Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413\u2013421 (2012).","journal-title":"Nat. Biotechnol."},{"key":"8507_CR68","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"8507_CR69","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome. BMC Bioinform.\u00a012, 323 (2011).","journal-title":"BMC Bioinform."},{"key":"8507_CR70","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1093\/bioinformatics\/bts196","volume":"28","author":"DS DeLuca","year":"2012","unstructured":"DeLuca, D. S. et al. RNA-SeQC: RNA-seq metrics for quality control and process optimization. Bioinformatics 28, 1530\u20131532 (2012).","journal-title":"Bioinformatics"},{"key":"8507_CR71","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41587-019-0322-9","volume":"38","author":"S Sarkizova","year":"2020","unstructured":"Sarkizova, S. et al. A large peptidome dataset improves HLA class I epitope prediction across most of the human population. Nat. Biotechnol. 38, 199\u2013209 (2020).","journal-title":"Nat. Biotechnol."},{"key":"8507_CR72","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","volume":"199","author":"V Jurtz","year":"2017","unstructured":"Jurtz, V. et al. NetMHCpan-4.0: improved peptide\u2013MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J. Immunol. 199, 3360\u20133368 (2017).","journal-title":"J. Immunol."},{"key":"8507_CR73","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature12912","volume":"505","author":"MS Lawrence","year":"2014","unstructured":"Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495\u2013501 (2014).","journal-title":"Nature"},{"key":"8507_CR74","doi-asserted-by":"publisher","DOI":"10.1172\/JCI151666","volume":"132","author":"PC Lee","year":"2022","unstructured":"Lee, P. C. et al. Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma. J. Clin. Invest. 132, e151666 (2022).","journal-title":"J. Clin. Invest."},{"key":"8507_CR75","first-page":"75","volume":"2","author":"DB Keskin","year":"2011","unstructured":"Keskin, D. B. et al. Direct identification of an HPV-16 tumor antigen from cervical cancer biopsy specimens. Front. Immunol. 2, 75 (2011).","journal-title":"Front. Immunol."},{"key":"8507_CR76","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587 (2021).","journal-title":"Cell"},{"key":"8507_CR77","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.cels.2019.03.003","volume":"8","author":"CS McGinnis","year":"2019","unstructured":"McGinnis, C. S., Murrow, L. M. & Gartner, Z. J. DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. Cell Syst. 8, 329\u2013337 (2019).","journal-title":"Cell Syst."},{"key":"8507_CR78","doi-asserted-by":"publisher","first-page":"979","DOI":"10.12688\/f1000research.73600.1","volume":"10","author":"PL Germain","year":"2021","unstructured":"Germain, P. L., Lun, A., Garcia Meixide, C., Macnair, W. & Robinson, M. D. Doublet identification in single-cell sequencing data using scDblFinder. F1000Research 10, 979 (2021).","journal-title":"F1000Research"},{"key":"8507_CR79","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289\u20131296 (2019).","journal-title":"Nat. Methods"},{"key":"8507_CR80","doi-asserted-by":"publisher","DOI":"10.1093\/gigascience\/giy083","volume":"7","author":"L Zappia","year":"2018","unstructured":"Zappia, L. & Oshlack, A. Clustering trees: a visualization for evaluating clusterings at multiple resolutions. Gigascience 7, giy083 (2018).","journal-title":"Gigascience"},{"key":"8507_CR81","unstructured":"Street, K., Movassagh, M. & Lundell, J. VDJdive: analysis tools for 10X V(D)J data. R package v.1.3.5. Bioconductor https:\/\/www.bioconductor.org\/packages\/release\/bioc\/html\/VDJdive.html (2024)."},{"key":"8507_CR82","doi-asserted-by":"publisher","first-page":"47","DOI":"10.12688\/f1000research.22139.1","volume":"9","author":"N Borcherding","year":"2020","unstructured":"Borcherding, N., Bormann, N. L. & Kraus, G. scRepertoire: an R-based toolkit for single-cell immune receptor analysis. F1000Research 9, 47 (2020).","journal-title":"F1000Research"},{"key":"8507_CR83","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1038\/s41596-019-0195-x","volume":"14","author":"S Li","year":"2019","unstructured":"Li, S. et al. RNase H-dependent PCR-enabled T-cell receptor sequencing for highly specific and efficient targeted sequencing of T-cell receptor mRNA for single-cell and repertoire analysis. Nat. Protoc. 14, 2571\u20132594 (2019).","journal-title":"Nat. Protoc."},{"key":"8507_CR84","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nmeth.3364","volume":"12","author":"DA Bolotin","year":"2015","unstructured":"Bolotin, D. A. et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat. Methods 12, 380\u2013381 (2015).","journal-title":"Nat. Methods"},{"key":"8507_CR85","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.immuni.2017.02.007","volume":"46","author":"JG Abelin","year":"2017","unstructured":"Abelin, J. G. et al. Mass spectrometry profiling of HLA-associated peptidomes in mono-allelic cells enables more accurate epitope prediction. Immunity 46, 315\u2013326 (2017).","journal-title":"Immunity"},{"key":"8507_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23324-4","volume":"12","author":"M Andreatta","year":"2021","unstructured":"Andreatta, M. et al. Interpretation of T cell states from single-cell transcriptomics data using reference atlases. Nat. Commun. 12, 2965 (2021).","journal-title":"Nat. Commun."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-08507-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-08507-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-08507-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T17:01:58Z","timestamp":1746205318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-08507-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":86,"journal-issue":{"issue":"8054","published-print":{"date-parts":[[2025,3,13]]}},"alternative-id":["8507"],"URL":"https:\/\/doi.org\/10.1038\/s41586-024-08507-5","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,5]]},"assertion":[{"value":"19 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Bristol-Myers Squibb provided ipilimumab, but no funding support for the clinical trial. D.A.B reports share options in Elephas; advisory board, consulting or personal fees from Cancer Expert Now, Adnovate Strategies, MDedge, CancerNetwork, Catenion, OncLive, Cello Health BioConsulting, PWW Consulting, Haymarket Medical Network, Aptitude Health, ASCO Post and Harborside, Targeted Oncology, Merck, Pfizer, MedScape, Accolade 2nd MD, DLA Piper, AbbVie, Compugen, Link Cell Therapies, Scholar Rock, NeoMorph, Nimbus, Exelixis, AVEO, Eisai and Elephas; and research support from Exelixis and AstraZeneca, outside the submitted work. B.A.M. discloses personal consulting fees from Arcus, Aveo, Bristol-Myers Squibb, Daiichi Sanko, Eisai, Exelixis, Genmab, Gilead, Hexagen, Pfizer and SeaGen, and institutional disclosures for Aveo, Bristol-Myers Squibb, Exelixis, Gilead, Pfizer and SeaGen. N.R.L. is a consultant and has received honoraria from Bayer, Seattle Genetics, Sanofi, Silverback, Fortress Biotech, Synox Therapeutics, Janssen and Astellas pharma, outside the submitted work. K.S. is now an employee and shareholder of Intellia Therapeutics, which has no contribution or affiliation to the work described in this article. S.K. is now an employee of Genentech. S.\u2009Sarkizova is now an employee of Moderna and holds stock (as of January 2024). J.B.I. reports receiving consulting fees from AstraZeneca outside the submitted work. S.\u00a0Signoretti reports receiving commercial research grants from Bristol-Myers Squibb, AstraZeneca, Exelixis, Merck, NiKang Therapeutics and Arsenal Biosciences; is a consultant\/advisory board member for Merck, AstraZeneca, Bristol Myers Squibb, CRISPR Therapeutics AG, AACR and NCI; receives royalties from Biogenex; and mentored several non-United States citizens on research projects with potential funding (in part) from non-United States sources\/Foreign Components. J.C.A. has served as a consultant for Remix Therapeutics, Ayala Pharmaceuticals, Cellestia, and on the scientific advisory board of NeuAPC, outside the submitted work. S.A.C. is a member of the scientific advisory boards of PTM BioLabs, Seer, StandUp2Cancer and PrognomIQ. I.L. serves as a consultant for PACT Pharma and has stock, is on the board and serves as a consultant for ennov1, and is on the board and holds equity in Nord Bio. G.G. receives research funds from IBM, Pharmacyclics\/Abbvie, Bayer, Genentech, Calico, Ultima Genomics, Inocras and Google and is also an inventor on patent applications filed by the Broad Institute related to MSMuTect, MSMutSig, POLYSOLVER, SignatureAnalyzer-GPU, MSEye and MinimuMM-seq. He is a founder, consultant and holds privately held equity in Scorpion Therapeutics; he is also a founder of, and holds privately held equity in, PreDICTA Biosciences. He was also a consultant to Merck. N.H. holds equity in and advises Danger Bio\/Related Sciences and Repertoire Immune Medicines, owns equity in BioNtech and receives research funding from Bristol Myers Squibb and Calico Life Sciences. D.S.N. owns stock in Madrigal Pharmaceuticals, outside the submitted work. K.J.L. holds equity in Standard BioTools and is on the scientific advisory board for MBQ Pharma. S.A.S. reports equity in Agenus, Agios Pharmaceuticals, Breakbio, Bristol-Myers Squibb and Lumos Pharma. S.A.S. is a consultant for Imunon and Jivanu therapeutics. E.F.F. is an equity holder in and consultant for BioNTech, an equity holder and scientific advisory board member of BioEntre, and a founder and equity holder of Dionis Therapeutics. C.J.W. is subject to a conflict-of-interest management plan for the reported studies because of her former competing financial interests in Neon Therapeutics, which was acquired by BioNTech. Under this plan, C.J.W. may not access identifiable data for human participants or otherwise participate directly in the Institutional Review Board-approved protocol reported herein. C.J.W.\u2019s contributions to the overall strategy and data analyses occurred on a de-identified basis. Patent applications have been filed on aspects of the described work entitled as follows: \u2018Compositions and methods for personalized neoplasia vaccines\u2019 (N.H., E.F.F. and C.J.W.), \u2018Methods for identifying tumour specific neoantigens\u2019 (N.H. and C.J.W.), \u2018Formulations for neoplasia vaccines\u2019 (E.F.F.) and \u2018Combination therapy for neoantigen vaccine\u2019 (N.H., C.J.W. and E.F.F.). The DFCI, the lead site of this trial, has a proprietary and financial interest in the personalized neoantigen vaccine. D.B.K. is a scientific advisor for Immunitrack, a wholly owned subsidiary of Eli Lilly and Company and Breakbio. D.B.K. owns equity in Affimed N.V., Agenus, Armata Pharmaceuticals, Breakbio, BioMarin Pharmaceuticals, Celldex Therapeutics, Editas Medicine, Immunitybio, Lexicon Pharmaceuticals, Summit Therapeutics and Viking Therapeutics. P.A.O. has received research funding from and\/or has advised Agenus, Amgen, Armo BioSciences Array, AstraZeneca\/MedImmune, Bristol-Meyers Squibb, Celldex, Compass Therapeutics, CytomX, Evaxion, Immunetune, Imunon, LGChem, Merck, Neon Therapeutics (now BioNTechUS), Novartis, Pharmajet, Phio, Pfizer, Oncorus, Roche\/Genentech, Servier and Xencor. Committees: NCCN. T.K.C. reports grants, personal fees and non-financial support from Roche and Genentech during the conduct of the study; and reports institutional and\/or personal, paid and\/or unpaid support for research, advisory boards, consultancy, and\/or honoraria from Alkermes, AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers-Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, Gilead, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Oncohost, Pfizer, Roche, Sanofi\/Aventis, Scholar Rock, Surface Oncology, Takeda, Tempest, Up-To-Date, CME events (Peerview, OncLive, MJH and others), outside the submitted work. Institutional patents filed on molecular alterations and immunotherapy response\/toxicity, and ctDNA. Equity: Tempest, Pionyr, Osel, Precede Bio, CureResponse, InnDura Therapeutics, Primium. Committees: NCCN, GU Steering Committee, ASCO\/ESMO, ACCRU, KidneyCan, ODAC. Mentored several non-United States citizens on research projects with potential funding (in part) from non-United States sources\/Foreign Components. The institution (Dana-Farber Cancer Institute) may have received additional independent funding of drug companies and\/or royalties potentially involved in research around the subject matter. G.M., V.C., E.B., C.R.T., A.P.V., C.F., J.F., A.B.A., N.R.S., Y.L., S.L., J.S., S.L.C., M.S.H., O.O., A.M., H.G., C.B.P., M.M., I.C., A.T., J.D.-C., A.A.H., B.S., J.M.S., L.E., L.R.O., S.G. and G.O. have no reported disclosures related to the current work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}